comparemela.com
Latest Breaking News On - Jnjinnovmedand janssen - Page 1 : comparemela.com
Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT
News Release Media Contacts: Suzanne Frost +1 416-317-0304 Brian Kenney +1 215-620-0111 .
United-kingdom
Madrid
Spain
James-wf-catto
Indianj-urol
Clin-urol
Obrian-kenney
Kiran-patel
Jnjinnovmedand-janssen
Exchange-commission
Drug-administration
Johnson
vimarsana © 2020. All Rights Reserved.